A bluetongue vaccine and methods of manufacture thereof
AssigneeBiovet Private Limited
InventorsTapas BHATTACHARYA, Shree Naravan SINGH
Life of this patent
Estimating the term…
Abstract
Disclosed is a novel vaccine formulation for prevention against Bluetongue virus infection in domestic and wild ruminants, cattle, goats, sheep, pigs, and any other mammals for commercial use. The antigen present in the vaccine is an inactivated antigen comprising 5 different serotypes of Bluetongue virus, thereby making a pentavalent vaccine formulation against Bluetongue virus infections. Also disclosed are method of adaptation of Bluetongue virus in suspension culture upto 2000 liters industrial size bioreactors, and inactivation techniques for preparation of the given vaccine formulation with the presence of suitable adjuvants and preservatives.
Claims9
A method of industrial cultivation of Bluetongue virus, the said method comprising, virus culture of Bluetongue virus in suspension BHK-21 cell lines in stainless steel vessels industrial bioreactor.
A method of adaptation of Bluetongue virus in BHK-21 cells in suspension culture capable of industrial production of Bluetongue vaccine.
A method of scale up of virus culture of Bluetongue virus on BHK-21 cells from T-175 flask to an industrial bioreactor of 250 liter batch volume, wherein the virus titer attained of the Bluetongue virus ranges from 10−5.5TCID50/ml to 10−7.0TCID50/ml within 48 hours to 72 hours of infection.
A method of scale up of virus culture of Bluetongue virus on BHK-21 cells from 250 liter batch volume to an industrial bioreactor of 2000 liter batch volume, wherein the virus titer attained of the Bluetongue virus ranges from 10−5.5TCID50/ml to 10−7.0TCID50/ml within 48 hours to 72 hours of infection.
A vaccine composition for the prophylaxis of animals from Bluetongue virus infection, comprising a vaccine antigen, wherein the said vaccine antigen comprises of Bluetongue virus serotypes BTV 1, BTV 2, BTV 10, BTV 16 and BTV 23, the said Bluetongue serotypes being adapted to infect BHK-21 cells in suspension cell line culture to obtain a virus titer from 10−5.5TCID50/ml to 10−7.0TCiD50/ml within 48 hours to 72 hours of infection thereby capable of conferring immune response against Bluetongue virus infections.
Dependencies are inferred from the claim text.